Awaiting development: Guidance and quality standards

Showing 251 to 260 of 335

Guidance and quality standards awaiting development
Title	Type
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]	Technology appraisal guidance
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]	Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433	Technology appraisal guidance
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal	Quality standard
Safeguarding adults in care homes	Quality standard
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237	Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]	Technology appraisal guidance